hVIVO plc Board Change (4848I)
June 20 2017 - 1:00AM
UK Regulatory
TIDMHVO
RNS Number : 4848I
hVIVO plc
20 June 2017
For immediate release 7.00am: 20 June 2017
HVIVO PLC
("hVIVO" or the "Company")
Board Change
hVIVO plc (AIM: HVO), a specialty biopharma company with
discovery and clinical testing capabilities, is pleased to announce
the appointment of Dr Trevor Phillips as a Non-Executive Director,
with immediate effect.
Trevor has over thirty years' of experience within the
pharmaceutical industry, including extensive international drug
development and corporate development responsibilities. He was
previously Chief Operations Officer and President of US Operations,
as well as a member of the Board, at Vectura Group plc, a FTSE 250
company listed on the London Stock Exchange focused on respiratory
diseases. Subsequent to joining Vectura in 2010, Trevor played an
integral leadership role in the company's successful development,
including the acquisition of Activaero GmbH in 2014 and the merger
with Skyepharma plc in 2016.
Prior to joining Vectura, Trevor held the roles of Chief
Executive Officer and Chief Operating Officer at Critical
Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty
pharmaceutical company. He has also held senior management
positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.),
Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc).
Trevor trained as a microbiologist at University of Reading,
obtaining a PhD in microbial biochemistry from the University of
Wales in 1986. He was awarded an MBA from Henley Management College
in 1997.
Jaime Ellertson, Non-Executive Chairman, commented:
"I would like to welcome Dr Trevor Phillips to hVIVO. Trevor
brings extensive respiratory drug development and commercialisation
experience to hVIVO, which will play a vital role in guiding our
partnering and collaboration strategies in respiratory and
infectious diseases. We believe Trevor will strengthen the Board as
we progress our precision medicine based inventions and products
forward towards commercialisation."
Dr Trevor Phillips, aged 56, is a director/partner or has been a
director/partner of the following companies/partnerships during the
previous five years:
Current
Prostratex Limited
Previous
Andaris (DDS) Limited
Andaris Group Limited
Innovata Biomed Limited
Innovata Limited
Microshot Limited
Protosome Limited
Qdose Limited
Quadrant Bioresources
Limited
Quadrant Drug Delivery
Limited
Quadrant Healthcare
(UK) Limited
Quadrant Healthcare
Limited
Quadrant Holdings Cambridge
Limited
Quadrant Technologies
Limited
Quadrant Trustee Limited
Skyepharma Limited
Vectura Delivery Devices
Limited
Vectura Group Investments
Limited
Vectura Group plc
Vectura Limited
Dr Trevor Phillips does not hold any ordinary shares in hVIVO
plc.
Save for the information disclosed above there is no other
information to be disclosed on Dr Trevor Phillips under Schedule
2(g) of the AIM Rules.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive
Officer)
Graham Yeatman (Chief Financial
& Business Officer)
Media Enquiries +1 919 710 9658
Susan Flood (Head of Marketing)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke
(Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster
Mitchell (UK) +44 203 727 1000
John Capodanno / Evan Smith
(US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with
discovery and clinical testing capabilities, is pioneering a
human-based analytical platform to accelerate drug discovery and
development in respiratory and infectious diseases. Leveraging
human disease models in flu, RSV and asthma exacerbation, the hVIVO
platform captures disease in motion, illuminating the entire
disease life cycle from healthy to sick and back to health. Based
in the UK, market leader hVIVO has conducted more than 45 clinical
studies, inoculated over 2000 volunteers and has three
first-in-class therapies currently in development with a growing
pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUKOARBUANAAR
(END) Dow Jones Newswires
June 20, 2017 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024